分化型甲状腺癌的遗传学现状
Actualities in genetics of differentiated thyroid cancer.
作者信息
Dobrescu R, Badiu C
机构信息
"C.I. Parhon" National Institute of Endocrinology - Research Laboratory, Bucharest, Romania.
"C.I. Parhon" National Institute of Endocrinology - Thyroid Related Disorders, Bucharest, Romania.
出版信息
Acta Endocrinol (Buchar). 2020 Jan-Mar;16(1):118-120. doi: 10.4183/aeb.2020.118.
Abstract
Genetics of cancer is a hot topic, an excellent example of translational medicine. Risk stratification, selection of cases for surgery in Bethesda categories 3 &4 FNAB are examples of the high impact of genetic evaluation in thyroid neoplasia.
摘要
癌症遗传学是一个热门话题，是转化医学的一个绝佳范例。风险分层、针对贝塞斯达分类3和4类细针穿刺活检（FNAB）病例选择手术，都是遗传学评估在甲状腺肿瘤中具有重大影响的实例。
相似文献
1
Actualities in genetics of differentiated thyroid cancer.分化型甲状腺癌的遗传学现状
Acta Endocrinol (Buchar). 2020 Jan-Mar;16(1):118-120. doi: 10.4183/aeb.2020.118.
2
TERT promoter mutations and their correlation with BRAF and RAS mutations in a consecutive cohort of 145 thyroid cancer cases.145例甲状腺癌连续队列中的TERT启动子突变及其与BRAF和RAS突变的相关性
Oncol Lett. 2018 Mar;15(3):2763-2770. doi: 10.3892/ol.2017.7675. Epub 2017 Dec 21.
3
The largest CAP-certified Chinese reference laboratory experience with the Bethesda system for reporting thyroid cytopathology: correlation with histologic and BRAF data.最大的采用贝塞斯达系统报告甲状腺细胞病理学的中国CAP认证参考实验室经验：与组织学和BRAF数据的相关性
J Am Soc Cytopathol. 2018 Jan-Feb;7(1):16-21. doi: 10.1016/j.jasc.2017.07.002. Epub 2017 Jul 26.
4
The utility of the Bethesda category and its association with BRAF mutation in the prediction of papillary thyroid cancer stage.贝塞斯达分类法在预测甲状腺乳头状癌分期中的效用及其与BRAF突变的关联。
Langenbecks Arch Surg. 2017 Mar;402(2):227-234. doi: 10.1007/s00423-017-1560-2. Epub 2017 Feb 3.
5
The rational use of fine needle aspiration biopsy (FNAB) in diagnosing thyroid nodules.细针穿刺活检（FNAB）在甲状腺结节诊断中的合理应用。
Minerva Endocrinol. 2006 Jun;31(2):159-72.
6
Role of ultrasonographic/clinical profile, cytology, and BRAF V600E mutation evaluation in thyroid nodule screening for malignancy: a prospective study.超声/临床特征、细胞学和 BRAF V600E 突变评估在甲状腺结节恶性肿瘤筛查中的作用：一项前瞻性研究。
J Clin Endocrinol Metab. 2012 Jul;97(7):2354-61. doi: 10.1210/jc.2011-3494. Epub 2012 Apr 24.
7
Evaluation of BRAF, RAS, RET/PTC, and PAX8/PPARg alterations in different Bethesda diagnostic categories: A multicentric prospective study on the validity of the 7-gene panel test in 1172 thyroid FNAs deriving from different hospitals in South Italy.评价 BRAF、RAS、RET/PTC 和 PAX8/PPARγ 改变在不同 Bethesda 诊断分类中的情况：在意大利南部不同医院的 1172 例甲状腺细针抽吸活检标本中进行的 7 基因 panel 检测的有效性的多中心前瞻性研究。
Cancer Cytopathol. 2020 Feb;128(2):107-118. doi: 10.1002/cncy.22217. Epub 2019 Dec 10.
8
Proposal for a novel management of indeterminate thyroid nodules on the basis of cytopathological subclasses.基于细胞病理学亚类的甲状腺结节性质不明的新型管理方案
Endocrine. 2017 Jul;57(1):98-107. doi: 10.1007/s12020-016-1105-4. Epub 2016 Sep 13.
9
Bethesda classification is a valuable guide for fine needle aspiration reports and highly predictive especially for diagnosing aggressive variants of papillary thyroid carcinoma.贝塞斯达分类法是细针穿刺报告的重要指南，尤其对诊断甲状腺乳头状癌的侵袭性变体具有高度预测性。
Cytopathology. 2017 Aug;28(4):259-267. doi: 10.1111/cyt.12384. Epub 2016 Sep 25.
10
Prognostic effects of TERT promoter mutations are enhanced by coexistence with BRAF or RAS mutations and strengthen the risk prediction by the ATA or TNM staging system in differentiated thyroid cancer patients.TERT 启动子突变的预后影响因与 BRAF 或 RAS 突变共存而增强，并通过 ATA 或 TNM 分期系统加强分化型甲状腺癌患者的风险预测。
Cancer. 2016 May 1;122(9):1370-9. doi: 10.1002/cncr.29934. Epub 2016 Mar 11.
引用本文的文献
1
PREDICTORS OF MULTIFOCAL PAPILLARY THYROID CANCER. DO THEY EXIST?多灶性乳头状甲状腺癌的预测因素。它们存在吗？
Acta Endocrinol (Buchar). 2022 Oct-Dec;18(4):424-428. doi: 10.4183/aeb.2022.424.
2
Comparison of surgical strategies in the treatment of low-risk differentiated thyroid cancer.比较低危分化型甲状腺癌的手术治疗策略。
BMC Endocr Disord. 2023 Jan 26;23(1):23. doi: 10.1186/s12902-023-01276-8.
本文引用的文献
1
Genomic and Transcriptomic Characteristics According to Size of Papillary Thyroid Microcarcinoma.根据甲状腺微小乳头状癌大小的基因组和转录组特征
Cancers (Basel). 2020 May 25;12(5):1345. doi: 10.3390/cancers12051345.
2
Obesity Is Associated with -Mutated Thyroid Cancer.肥胖与 -突变型甲状腺癌相关。
Thyroid. 2020 Oct;30(10):1518-1527. doi: 10.1089/thy.2019.0654. Epub 2020 May 4.
3
Molecular therapeutics for anaplastic thyroid cancer.间变性甲状腺癌的分子治疗。
Semin Cancer Biol. 2020 Apr;61:23-29. doi: 10.1016/j.semcancer.2020.01.005. Epub 2020 Jan 25.
4
Association between TERT promoter mutations and clinical behaviors in differentiated thyroid carcinoma: a systematic review and meta-analysis.TERT 启动子突变与分化型甲状腺癌临床行为的关系：系统评价和荟萃分析。
Endocrine. 2020 Jan;67(1):44-57. doi: 10.1007/s12020-019-02117-2. Epub 2019 Oct 26.
5
Molecular Alterations in Thyroid Cancer: From Bench to Clinical Practice.甲状腺癌的分子改变：从基础到临床实践。
Genes (Basel). 2019 Sep 13;10(9):709. doi: 10.3390/genes10090709.
6
Integrative analysis of genomic and transcriptomic characteristics associated with progression of aggressive thyroid cancer.整合分析与侵袭性甲状腺癌进展相关的基因组和转录组特征。
Nat Commun. 2019 Jun 24;10(1):2764. doi: 10.1038/s41467-019-10680-5.
7
A Clinical Overview of Telomerase-Associated Aberrancies in Follicular Thyroid Tumors as Diagnostic and Prognostic Markers: Tert Alert!甲状腺滤泡性肿瘤中端粒酶相关异常作为诊断和预后标志物的临床概述：TERT预警！
Scand J Surg. 2020 Sep;109(3):187-192. doi: 10.1177/1457496919850434. Epub 2019 May 26.
8
TERT promoter mutations identify a high-risk group in metastasis-free advanced thyroid carcinoma.TERT 启动子突变鉴定出无转移的晚期甲状腺癌中的高危人群。
Eur J Cancer. 2019 Feb;108:41-49. doi: 10.1016/j.ejca.2018.12.003. Epub 2019 Jan 12.
9
Low Prevalence of TERT Promoter, BRAF and RAS Mutations in Papillary Thyroid Cancer in the Greek Population.希腊人群甲状腺乳头状癌中 TERT 启动子、BRAF 和 RAS 突变的低发生率。
Pathol Oncol Res. 2020 Jan;26(1):347-354. doi: 10.1007/s12253-018-0497-2. Epub 2018 Oct 25.
10
Genetic Analysis of 779 Advanced Differentiated and Anaplastic Thyroid Cancers.779 例高级别分化型和间变性甲状腺癌的遗传学分析。
Clin Cancer Res. 2018 Jul 1;24(13):3059-3068. doi: 10.1158/1078-0432.CCR-18-0373. Epub 2018 Apr 3.
Zotero 插件